Journal
DIGESTION
Volume 90, Issue 2, Pages 130-136Publisher
KARGER
DOI: 10.1159/000365783
Keywords
Crohn's disease; Adalimumab; Anti-tumor necrosis factor antagonist; Clinical remission; Bowel resection
Categories
Funding
- Ajinomoto Pharmaceuticals Co., Ltd.
- Eisai Co., Ltd.
- Mitsubishi Tanabe Pharma Corporation
- ZERIA Co., Ltd.
- AstraZeneca Co., Ltd.
- Boston Scientific Japan Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- KYORIN Pharmaceutical Co., Ltd.
- JIMRO Co., Ltd.
- ZERIA Pharmaceutical Co., Ltd.
- Abbvie
- Takeda Pharmaceutical Co., Ltd.
Ask authors/readers for more resources
Background: We evaluated the clinical efficacy of adalimumab (ADA) for Crohn's disease (CD) and analyzed predictive factors for clinical remission and long-term prognosis. Methods: We retrospectively reviewed the medical records of 45 patients treated with ADA for CD at Keio University Hospital between October 2010 and March 2014. Clinical remission was defined as a Harvey-Bradshaw index of <= 4. Results: Twenty-eight of 45 patients (62.2%) achieved clinical remission at week 4. Among these 28 patients, 18 patients (64.3%) maintained clinical remission at week 26, and among these, 16 patients (88.9%) maintained clinical remission at week 52. Absence of a history of bowel resection and absence of prior anti-tumor necrosis factor (anti-TNF) therapy were significant predictive factors for clinical remission at week 4 upon multivariate logistic regression analyses. Younger age and a disease duration of <= 3 years correlated with clinical remission at week 26 upon univariate analyses. Patients without a history of bowel resection showed significantly better long-term prognosis than those with a history of bowel resection (p = 0.01). None of the patients contracted a serious infectious disease. Conclusions: Younger age, shorter duration of disease, being naive to anti-TNF antagonists, and absence of a history of bowel resection were associated with the efficacy of ADA in CD patients. (C) 2014 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available